Artificial Pancreas Market Size, Share, Trends, Growth Outlook

Artificial Pancreas Market is estimated to increase at a growth rate of 9.1% CAGR over the forecast period from 2024 to 2030.

The global Artificial Pancreas Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Threshold Suspend Device, Non-Threshold Suspend Device, Control to Range System, Control to Target System), By Treatment (Insulin only, Bi-hormonal, Hybrid).

An Introduction to Artificial Pancreas Market in 2024

The Artificial Pancreas Market is at the forefront of diabetes management, offering a revolutionary approach to insulin delivery and glucose control. In 2024, artificial pancreas systems integrate continuous glucose monitoring (CGM) technology with insulin pumps and automated algorithms, providing precise and personalized insulin dosing in real time. These closed-loop systems aim to mimic the function of the human pancreas, optimizing glycemic control, reducing hypoglycemia episodes, and empowering individuals with diabetes to lead more flexible and active lifestyles.

Artificial Pancreas Market Competitive Landscape

The global Artificial Pancreas Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Artificial Pancreas Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Artificial Pancreas Industry include- Admetsys Corp, Beta Bionics Inc, Bigfoot Biomedical Inc, Defymed SAS, Dexcom Inc, Inreda Diabetic B.V., Insulet Corp, Medtech Life Pvt. Ltd, Medtronic Plc, Tandem Diabetes Care Inc.

Artificial Pancreas Market Trend: Advancements in Closed-Loop Systems

In the Artificial Pancreas market, a significant trend is the advancement of closed-loop systems for automated insulin delivery. Closed-loop systems, also known as artificial pancreas systems, combine continuous glucose monitoring (CGM) with insulin infusion pumps and control algorithms to automatically adjust insulin delivery in response to changing blood glucose levels. This trend represents a shift towards more personalized and precise diabetes management, offering improved glycemic control, reduced risk of hypoglycemia, and enhanced quality of life for individuals with type 1 diabetes. Continued innovation in closed-loop technology is driving market growth and adoption of artificial pancreas systems as a preferred treatment option for diabetes management.

Artificial Pancreas Market Driver: Rising Prevalence of Diabetes

A key driver for the Artificial Pancreas market is the rising prevalence of diabetes worldwide, particularly type 1 diabetes. As the incidence of diabetes continues to increase due to factors such as sedentary lifestyles, unhealthy diets, and obesity, there's a growing need for effective and convenient insulin delivery solutions. Artificial pancreas systems address this need by offering automated glucose management, reducing the burden of diabetes management on patients and caregivers, and improving overall health outcomes. The increasing adoption of continuous glucose monitoring devices and advancements in insulin pump technology further drive market growth by providing the foundation for closed-loop systems.

Artificial Pancreas Market Opportunity: Integration of Artificial Intelligence and Machine Learning

An opportunity exists in the integration of artificial intelligence (AI) and machine learning (ML) algorithms to optimize closed-loop control strategies in artificial pancreas systems. By leveraging AI and ML techniques to analyze vast amounts of patient data, including glucose levels, insulin dosing, meal intake, and physical activity, there's potential to enhance the performance and customization of closed-loop algorithms. This opportunity enables the development of adaptive and predictive control algorithms that can anticipate and respond to individual patient needs, variability, and lifestyle changes, resulting in improved glycemic outcomes and patient satisfaction. Collaboration between diabetes researchers, technology developers, and regulatory agencies can accelerate the integration of AI and ML into artificial pancreas systems, unlocking new opportunities for innovation and market growth in the Artificial Pancreas segment.

Market Share Analysis: Control to Target System is the fastest growing segment in the Artificial Pancreas industry

Among the different types of artificial pancreas systems, the segment experiencing the fastest growth is the Control to Target System. This innovative technology offers precise and personalized insulin delivery by continuously monitoring glucose levels and automatically adjusting insulin dosages to maintain blood sugar within a target range. Control to Target Systems represent a significant advancement in diabetes management, particularly for individuals with type 1 diabetes, as they help minimize the risk of hypo- and hyperglycemia while optimizing glycemic control. With the increasing prevalence of diabetes worldwide and the growing demand for advanced treatment options that improve patient outcomes and quality of life, the Control to Target System segment is poised for rapid expansion. Additionally, ongoing research and development efforts aimed at enhancing the functionality, accuracy, and usability of these systems are expected to further drive their adoption and contribute to their sustained growth in the healthcare market.

Artificial Pancreas Market Segmentation

By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Artificial Pancreas Companies

Admetsys Corp
Beta Bionics Inc
Bigfoot Biomedical Inc
Defymed SAS
Dexcom Inc
Inreda Diabetic B.V.
Insulet Corp
Medtech Life Pvt. Ltd
Medtronic Plc
Tandem Diabetes Care Inc
* List not Exhaustive

Reasons to Buy the Artificial Pancreas Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Artificial Pancreas Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Artificial Pancreas Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Artificial Pancreas Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Artificial Pancreas Market Size Outlook, $ Million, 2021 to 2030
3.2 Artificial Pancreas Market Outlook by Type, $ Million, 2021 to 2030
3.3 Artificial Pancreas Market Outlook by Product, $ Million, 2021 to 2030
3.4 Artificial Pancreas Market Outlook by Application, $ Million, 2021 to 2030
3.5 Artificial Pancreas Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Artificial Pancreas Industry
4.2 Key Market Trends in Artificial Pancreas Industry
4.3 Potential Opportunities in Artificial Pancreas Industry
4.4 Key Challenges in Artificial Pancreas Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Artificial Pancreas Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Artificial Pancreas Market Outlook by Segments
7.1 Artificial Pancreas Market Outlook by Segments, $ Million, 2021- 2030
By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid
8 North America Artificial Pancreas Market Analysis and Outlook To 2030
8.1 Introduction to North America Artificial Pancreas Markets in 2024
8.2 North America Artificial Pancreas Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Artificial Pancreas Market size Outlook by Segments, 2021-2030
By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid
9 Europe Artificial Pancreas Market Analysis and Outlook To 2030
9.1 Introduction to Europe Artificial Pancreas Markets in 2024
9.2 Europe Artificial Pancreas Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Artificial Pancreas Market Size Outlook by Segments, 2021-2030
By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid
10 Asia Pacific Artificial Pancreas Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Artificial Pancreas Markets in 2024
10.2 Asia Pacific Artificial Pancreas Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Artificial Pancreas Market size Outlook by Segments, 2021-2030
By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid
11 South America Artificial Pancreas Market Analysis and Outlook To 2030
11.1 Introduction to South America Artificial Pancreas Markets in 2024
11.2 South America Artificial Pancreas Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Artificial Pancreas Market size Outlook by Segments, 2021-2030
By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid
12 Middle East and Africa Artificial Pancreas Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Artificial Pancreas Markets in 2024
12.2 Middle East and Africa Artificial Pancreas Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Artificial Pancreas Market size Outlook by Segments, 2021-2030
By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Admetsys Corp
Beta Bionics Inc
Bigfoot Biomedical Inc
Defymed SAS
Dexcom Inc
Inreda Diabetic B.V.
Insulet Corp
Medtech Life Pvt. Ltd
Medtronic Plc
Tandem Diabetes Care Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Threshold Suspend Device
Non-Threshold Suspend Device
Control to Range System
Control to Target System
By Treatment
Insulin only
Bi-hormonal
Hybrid